Xuantai Pharmaceutical (688247.SH): The company did not implement a share buyback in December.

On January 1, Gelonghui announced that Xuantai Pharmaceutical (688247.SH) reported that by December 2024, the company had not implemented any share buybacks. As of December 31, 2024, the company had repurchased a total of 4.3361 million shares through the centralized bidding trading system of the Shanghai Exchange, accounting for 0.96% of the company's total equity. The highest purchase price was 8.98 yuan/share, the lowest was 7.40 yuan/share, and the total amount paid was 36.126 million yuan (excluding stamp duty, transaction commissions, and other transaction fees).

Gelonghui FinanceJan 1 15:40

Express News | The opening of the tenth batch of national Pharmaceutical centralized purchasing has prompted nearly 30 listed companies to announce their products are likely to be selected after the market close.

BreakingsDec 13, 2024 21:24

Express News | Xuantai Pharmaceutical: Carbonate Sevilamer Tablets and Moxidectin Tablets have been selected for the national centralized Pharmaceutical procurement.

BreakingsDec 13, 2024 18:11

Xuantai Pharmaceutical (688247.SH): The company's products are participating in the national organization for centralized volume-based procurement of Pharmaceuticals and are expected to be selected.

Gelonghui, on December 13, announced that Xuantai Pharmaceutical (688247.SH) participated in the bidding for the tenth batch of national organized pharmaceutical centralized procurement. According to the document "Announcement of Proposed Selected Results for National Pharmaceutical Centralized Procurement" released by the National Organized Pharmaceutical Joint Procurement Office on December 12, 2024, the company's products, carbonic acid seviram tablets and macitentan tablets (products developed in collaboration with Puji Biological Technology (Taizhou) Co., Ltd.), were selected for this centralized procurement, while posaconazole enteric-coated tablets and tofacitinib citric acid extended-release tablets were not selected for this centralized procurement. The proposed selection results for this centralized procurement are intended.

Gelonghui FinanceDec 13, 2024 18:00

Express News | The stocks of State-owned Enterprise Reform concept stocks in Shanghai have collectively strengthened, with several stocks such as Shanghai Fudan Forward S&T reaching a price limit.

BreakingsDec 11, 2024 09:30

Express News | Summary of shareholding reductions of listed companies on November 27.

BreakingsNov 27, 2024 22:31